Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Monica Barbolini"'
Autor:
Fabio Canino, Monica Barbolini, Ugo De Giorgi, Tommaso Fontana, Valeria Gaspari, Caterina Gianni, Lorenzo Gianni, Antonio Maestri, Santino Minichillo, Luca Moscetti, Antonella Mura, Stefania Vittoria Luisa Nicoletti, Claudia Omarini, Rachele Pagani, Samanta Sarti, Angela Toss, Claudio Zamagni, Riccardo Cuoghi Costantini, Federica Caggia, Giuseppina Antonelli, Federica Baglio, Lorenzo Belluzzi, Giulio Martinelli, Salvatore Natalizio, Ornella Ponzoni, Massimo Dominici, Federico Piacentini
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-18 (2024)
Abstract Background The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the pathological complete response (pCR) rate, with
Externí odkaz:
https://doaj.org/article/1ac6fc48a61047d696aefc89f35bee02
Autor:
Fabio Canino, Antonio Tornincasa, Stefania Bettelli, Samantha Manfredini, Monica Barbolini, Luca Moscetti, Claudia Omarini, Angela Toss, Fabio Tamburrano, Giuseppina Antonelli, Federica Baglio, Lorenzo Belluzzi, Giulio Martinelli, Salvatore Natalizio, Ornella Ponzoni, Massimo Dominici, Federico Piacentini
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 5, p 2490 (2024)
Over the last two decades, the use of Next-Generation Sequencing (NGS) in medical oncology has increased the likelihood of identifying druggable mutations that may be potentially susceptible to targeted treatments. The European Society for Medical On
Externí odkaz:
https://doaj.org/article/11b13a3cdc5049b8a1893642589e9994
Autor:
Claudia Omarini, Federico Piacentini, Isabella Sperduti, Krisida Cerma, Monica Barbolini, Fabio Canino, Cecilia Nasso, Christel Isca, Federica Caggia, Massimo Dominici, Luca Moscetti
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Current guidelines consider T-DM1 the standard 2nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1st line treatment. Despite this, there are no prospec
Externí odkaz:
https://doaj.org/article/e270a0a9d2444a0195b5a1e7d9648de1
Autor:
Angela Toss, Marta Venturelli, Monica Civallero, Claudia Piombino, Federica Domati, Guido Ficarra, Francesca Combi, Eleonora Cabitza, Federica Caggia, Elena Barbieri, Monica Barbolini, Luca Moscetti, Claudia Omarini, Federico Piacentini, Giovanni Tazzioli, Massimo Dominici, Laura Cortesi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionTriple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and worse overall survival. Risk factors for relapse in this subset
Externí odkaz:
https://doaj.org/article/817c65a0954542c8a81c9e2fe03455f1
Autor:
Claudia Omarini, Federico Piacentini, Isabella Sperduti, Monica Barbolini, Chrystel Isca, Angela Toss, Laura Cortesi, Elena Barbieri, Massimo Dominici, Luca Moscetti
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Elderly patients are underrepresented in clinical study where combined endocrine strategies were compared to endocrine therapy (ET) in hormone receptors positive, HER2 negative, metastatic breast cancer. The role of the new endocr
Externí odkaz:
https://doaj.org/article/30245269f8334eaebbed057edb937585
Autor:
Krisida Cerma, Federico Piacentini, Luca Moscetti, Monica Barbolini, Fabio Canino, Antonio Tornincasa, Federica Caggia, Sara Cerri, Alessia Molinaro, Massimo Dominici, Claudia Omarini
Publikováno v:
Biomedicines, Vol 11, Iss 1, p 109 (2023)
Breast cancer (BC) is the most common women cancer and cause of cancer death. Despite decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest in several cases. The phosphatidylinositol 3-kinase (PI3K)/protein kina
Externí odkaz:
https://doaj.org/article/1b63fd5fe7b546fdbaa5176930656df8
Autor:
Fabio Canino, Federico Piacentini, Claudia Omarini, Angela Toss, Monica Barbolini, Patrizia Vici, Massimo Dominici, Luca Moscetti
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 13, p 7079 (2022)
Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment for HR+/HER2- metastatic breast cancer (mBC). Primary or secondary endocrine resistance could develop; however validated biomarkers capable of predic
Externí odkaz:
https://doaj.org/article/af11b86ee3bd437388ddf8946f0bed4d
Autor:
Claudia Omarini, Stefania Bettelli, Samantha Manfredini, Monica Barbolini, Chrystel Isca, Giulia Cortesi, Antonino Maiorana, Giovanni Tazzioli, Massimo Dominici, Federico Piacentini
Publikováno v:
Translational Oncology, Vol 13, Iss 9, Pp 100794- (2020)
Introduction: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy (NACT) predict survival outcomes. Patients achieving less than pathological complete response (pCR) have a worse prognosis, however, th
Externí odkaz:
https://doaj.org/article/74ac457ff3604c6aad4b57d0160de40e
Publikováno v:
Breast, Vol 52, Iss , Pp 132-133 (2020)
Externí odkaz:
https://doaj.org/article/3d71678c69be4925995be02c1491fb8b
Autor:
Antonio Tornincasa, Fabio Canino, Lucia Trudu, Monica Barbolini, Luca Moscetti, Claudia Omarini, Massimo Dominici, Federico Piacentini
Publikováno v:
Archives of Clinical and Medical Case Reports.